Company intelligence / Profile preview

SurgaColl Technologies

Ownership: Private
Development stage: Commercial

Overview

SurgaColl Technologies develops novel regenerative medical devices based on collagen biomaterials for surgical treatment of bone and cartilage diseases. Its lead product HydroxyColl has shown initial clinical use in maxillofacial surgery and will enter further orthopedic studies. ChondroColl targets knee cartilage regeneration and is progressing through European regulatory approval.

Therapeutic areas: OtherRheumatology
Modalities: DeviceHydrogel-based drug delivery therapyProtein
Industry: Surgical Medical Devices

Drug pipeline

2 assets

HydroxyColl

Commercial

Indications: Bone defects

1 more asset in the full pipeline.

Request access →

Partnerships

GM&C Life Sciences Fund/Catapult VenturesJulz CoRoyal College of Surgeons in Ireland/Tissue Engineering Research Group

Beyond the preview

Go deeper on SurgaColl Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SurgaColl Technologies.

Explore the full profile